News

LEXINGTON, KY / ACCESS Newswire / June 23, 2026 / NX Development Corp. recently celebrated the one-year anniversary of Gleolan’s return to our commercial control and we would like to take this opportunity to thank our loyal customers for their continued support. We are proud to report that Gleolan has achieved record-breaking unit sales along with significant growth…

LEXINGTON, KY – April 6, 2026 – NX Development Corp (NXDC) is pleased to announce that after successfully completing the data analysis of our MEN-301 Study of the use of Gleolan® (aminolevulinic acid HCl)  to enhance visualization of newly diagnosed or recurrent meningioma, we have submitted these data to the FDA for review as part…

LEXINGTON, KY., April 23, 2025 – Today, NX Development Corp (“NXDC”), a Lexington, KY-based life sciences company, announced the return of the sales and marketing rights for Gleolan® (aminolevulinic acid HCl) from Medexus Pharmaceuticals. As the company that first launched the product in 2017, NXDC has held the marketing authorization for Gleolan for the past 7…

LEXINGTON, Ky., June 21, 2024 (Newswire.com) – NX Development Corp. (NXDC) is pleased to announce a significant milestone. Following the FDA’s Orphan Designation for the diagnostic management of ovarian, fallopian tube, and primary peritoneal cancer earlier this year, our first patient was recently enrolled in and successfully completed her surgery with Gleolan as part of our…

PRESS RELEASE•MAR 5, 2024 LEXINGTON, Ky., March 5, 2024 (Newswire.com) – NX Development Corp. (NXDC) has achieved another milestone as we proudly announce the recent granting of orphan-drug status by the U.S. Food and Drug Administration (FDA) for Gleolan (aminolevulinic acid HCl). This designation was provided for the “real-time detection and visualization of epithelial ovarian tumors during…